settings. IITs may or may not involve investigational new drugs (INDs), and their scope ranges from interventional to observational research.

CDSCO and NDCTR 2019 Interpretation

The NDCTR 2019 brought clarity to the handling of IITs, especially those not involving new drug approvals. As per the rules, IITs using already approved drugs within approved indications do not require formal CDSCO permission, provided all institutional and ethics oversight mechanisms are followed. However, if an IIT explores new indications, combinations, or routes of administration, or uses an unapproved drug or device, then CDSCO approval is mandatory even for academic trials.

ICMR Guidelines and Institutional Oversight

The 2017 National Ethical Guidelines for Biomedical and Health Research Involving Human Participants by ICMR provide foundational guidance on IITs. These emphasize the critical role of the Ethics Committee (EC), scientific review committees, and institutional responsibilities in approving and monitoring such trials. ICMR also advises clear delineation of roles between investigator and institutional sponsor, especially when research involves vulnerable populations or public funding.

Core Clinical Trial Insights

Ethics Committee Review: Mandatory for All IITs

Whether or not CDSCO approval is required, all IITs must undergo thorough EC review. The EC assesses the scientific merit, risk-benefit ratio, informed consent process, data privacy measures, and safety oversight plans. IITs must use ECs registered with CDSCO under Rule 8 of NDCTR 2019.

When is CDSCO Approval Required for IITs?

As per Rule 20 of NDCTR 2019, CDSCO approval is needed when an IIT involves:

• New chemical or biological entities (not approved in India)
• New indications or dose modifications of approved drugs
• Unapproved medical devices
• Global clinical trial (GCT) settings involving Indian patients

In such cases, Form CT-04 must be submitted with full protocol, investigator CV, IB (Investigator’s Brochure), EC approval, and undertaking as per Form CT-02.

Academic Sponsor Responsibilities

In IITs, the investigator assumes the role of the sponsor. This includes:

• Protocol development and version control
• Oversight of data collection, safety reporting, and monitoring
• Managing study budget and grant funding
• Ensuring GCP compliance and regulatory documentation

The institution (e.g., medical college, research center) often acts as co-sponsor or provides the infrastructure and oversight through Research Cells or Clinical Trial Units (CTUs).

Safety Reporting in IITs

IIT investigators must comply with safety reporting requirements. This includes:

• Serious Adverse Events (SAE) reports within 24 hours to EC and CDSCO (when applicable)
• Annual safety summaries to the EC
• Prompt reporting of protocol deviations, violations, and early terminations

For IITs approved by CDSCO, investigators must follow Rule 42–45 for SAE documentation, including timelines and causality assessment formats.

Documentation and Trial Master File (TMF) Expectations

IITs must maintain trial documents per GCP guidelines, including:

• Approved protocol and amendments
• Informed consent forms (ICF) and logs
• Investigator’s Brochure (if applicable)
• SAE reports and EC correspondence
• Monitoring visit reports (if monitoring is conducted)

These documents must be archived for a minimum of five years post-study, or longer if funding agencies require.

Funding and Conflict of Interest Management

IITs may receive financial support from government bodies (ICMR, DBT, DST), private pharma, or international collaborators. In all cases:

• Funding arrangements must be disclosed to the EC
• Ownership of data and publication rights must be clarified
• Conflict of interest declarations are mandatory

Protocol Amendments and Administrative Changes

Any change to the study protocol, PI, or risk/benefit profile must be approved by the EC before implementation. For CDSCO-approved IITs, such changes require submission through Form CT-10 for amendment notification. Failure to notify could lead to study suspension or investigator blacklisting.

Use of Clinical Trial Registry-India (CTRI)

All interventional IITs must be prospectively registered in CTRI before enrollment. This ensures transparency and allows public access to trial information. CTRI entries should be regularly updated to reflect protocol amendments, site additions, or recruitment status changes.

Monitoring and Quality Assurance in IITs

While IITs often lack formal CRO engagement, internal monitoring processes are essential. ICMR recommends:

• Appointment of a Study Monitor from within the institution
• Periodic data review and source data verification (SDV)
• Quality audits for GCP compliance

Public-funded IITs may be subject to external audits from funding agencies or government oversight bodies like CAG or DST monitors.

Best Practices & Preventive Measures

• Establish an Institutional Clinical Trials Committee (ICTC) for oversight
• Train investigators and site staff in ICH-GCP
• Use standardized SOPs for documentation and safety reporting
• Ensure CTRI registration and transparency measures are followed
• Maintain financial and publication agreements in writing

Scientific & Regulatory Evidence

• NDCTR 2019: Rules 20, 25, 26, and 42–45 outline IIT responsibilities
• ICMR Ethical Guidelines 2017: Section 3.4 on academic clinical research
• WHO GCP Handbook: Sections 1.25–1.27 defining sponsor-investigator obligations
• ICH E6(R2): Section 4.1 and 5.0 applicable to IITs globally

Special Considerations

Multicenter IITs in India

When an IIT is conducted across multiple centers in India, each participating site must obtain independent EC approval. Coordinating investigators must ensure harmonization of ICFs, protocol adherence, and data flow. Institutions may designate a central project management office to coordinate oversight and documentation.

IITs Involving Vulnerable Populations

Trials involving children, pregnant women, or tribal populations require heightened ethical scrutiny. Investigators must include specialized EC members (e.g., pediatrician, social worker) and ensure community consent or representative engagement. Audio-visual consent is mandated in such trials under NDCTR Rule 7.

When Sponsors (Investigators) Should Seek Regulatory Advice

• Before initiating an IIT with unapproved drugs or devices
• When adding international collaborators or exporting biospecimens
• To clarify CDSCO submission formats and forms (CT-04, CT-10, etc.)
• When intending to publish data from GCTs or pivotal findings
• To address safety reporting queries or SAE timelines

FAQs

1. Do all IITs in India need CDSCO approval?

No. Only those involving unapproved drugs, new indications, or global trials require CDSCO approval. Others need EC approval and CTRI registration.

2. Is ethics committee approval mandatory for observational IITs?

Yes. All IITs involving human participants, whether interventional or observational, require prior EC review and clearance.

3. Can pharma companies fund IITs?

Yes, but the funding must be transparent, without undue influence on study design, data ownership, or publication. All such relationships must be disclosed.

4. What are the reporting timelines for SAEs in IITs?

Initial SAE reports must be submitted within 24 hours to the EC and CDSCO (if applicable), followed by detailed follow-up within 14 days.

5. Are IITs audited in India?

Yes. They may be audited by institutional QA teams, funding agencies, or even CDSCO in case of complaints or noncompliance reports.

6. Can an IIT be retrospective?

No. Interventional IITs must be prospectively approved and registered. Retrospective trials lack ethical clearance and are not GCP-compliant.

7. Is CTRI registration mandatory for IITs?

Yes. As per ICMR guidelines and journal requirements, prospective CTRI registration is mandatory before subject enrollment.

Conclusion

Investigator-Initiated Trials are vital to India’s clinical research ecosystem. However, regulatory responsibilities under NDCTR 2019, ethical obligations under ICMR, and operational demands under GCP must be clearly understood by academic investigators. With structured planning, transparent funding, and strong institutional support, IITs can generate high-quality data that informs clinical practice while upholding participant safety and scientific integrity.